By: Maribel Yoo On: June 20, 2018 In: Nexus Strategy, Portfolio Comments: 0
WindMIL Logo

When it comes to cell therapy – cell source matters. WindMIL Therapeutics is harnessing the power of bone marrow derived lymphocytes (MILs™) to develop ground-breaking immunotherapies to treat cancer patients. The bone marrow is a natural reservoir of T cells with unique advantages including inherent tumor-specificity. WindMIL has perfected an efficient and rapid process to extract, activate and expand MILs™ for future commercial applications. Its  lead program is in a large Phase 2b study in high-risk multiple myeloma with additional programs in solid tumors using MILs™ advancing to the clinic. WindMIL is also advancing programs to supercharge MILs™ through genetic-modification.

Deal Source

Dr. Drew Pardoll

Board Representation

George Petrocheilos